Sean E McGuire, MD, PhD

Peer-Reviewed Articles

1. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. e-Pub 2023. PMID: 37022702.
2. Zamarbide Losada JN, Sulpice E, Combe S, Almeida GS, Leach DA, Choo J, Protopapa L, Hamilton MP, McGuire S, Gidrol X, Bevan CL, Fletcher CE. Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-resistant breast cancer. J Endocrinol 256(3), 2023. e-Pub 2023. PMID: 36622663.
3. McGuire SE. Deciphering Genomic Risk in Prostate Cancer-Ready for Prime Time. JAMA Oncol 7(4):553-554, 2021. e-Pub 2021. PMID: 33570544.
4. Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 39(40):6265-6285, 2020. e-Pub 2019. PMID: 31383940.
5. Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N. Correction: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 39(40):6387-6392, 2020. e-Pub 2020. PMID: 32820250.
6. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys 107(5):982-985, 2020. e-Pub 2020. PMID: 32353391.
7. Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol 17(4):214-231, 2020. e-Pub 2020. PMID: 32112053.
8. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open 3(3):e201255, 2020. e-Pub 2020. PMID: 32191331.
9. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2019. PMID: 31742674.
10. Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, Gaughan L, Swain A, Lupold SE, de Bono JS, McGuire SE, Gidrol X, Bevan CL. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene 38(28):5700-5724, 2019. e-Pub 2019. PMID: 31043708.
11. Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, Augustyn AA, Frank SJ, Choi S, Hoffman KE, Nguyen QN, McGuire SE, Pollack A, Anscher MS. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys 104(4):790-797, 2019. e-Pub 2019. PMID: 30836166.
12. Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, Saha PK, Panigrahi A, Walker C, Zong L, Martini-Stoica H, Chen R, Rajapakshe K, Coarfa C, Sreekumar A, Mitsiades N, Bankson JA, Ittmann MM, O'Malley BW, Putluri N, McGuire SE. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab 1(1):70-85, 2019. e-Pub 2018. PMID: 31198906.
13. Lin C, Salzillo TC, Bader DA, Wilkenfeld SR, Awad D, Pulliam TL, Dutta P, Pudakalakatti S, Titus M, McGuire SE, Bhattacharya PK, Frigo DE. Prostate Cancer Energetics and Biosynthesis. Adv Exp Med Biol 1210:185-237, 2019. PMID: 31900911.
14. Koh EH, Chernis N, Saha PK, Xiao L, Bader DA, Zhu B, Rajapakshe K, Hamilton MP, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM. miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes 67(12):2541-2553, 2018. e-Pub 2018. PMID: 30002134.
15. Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, Pugh TJ, Frank SJ, Kudchadker RJ, Du W, Kuban DA. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol 36(29):2943-2949, 2018. e-Pub 2018. PMID: 30106637.
16. Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol 41(6):558-567, 2018. e-Pub 2016. PMID: 27635624.
17. Kuhn JJ, Lavender VH, Hunter LL, McGuire SE, Meinzen-Derr J, Keith RW, Greinwald JH. Ocular Vestibular Evoked Myogenic Potentials: Normative Findings in Children. J Am Acad Audiol 29(5):443-450, 2018. PMID: 29708493.
18. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121(4):540-548, 2018. e-Pub 2017. PMID: 28941030.
19. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire SE, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys 100(2):374-382, 2018. e-Pub 2017. PMID: 29229325.
20. Holliday EB, Kuban DA, Levy LB, Bolukbasi Y, Master P, Choi S, Nguyen Q, McGuire SE, Mahmood U, Frank SJ, Hoffman KE. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis 20(4):389-394, 2017. e-Pub 2017. PMID: 28462945.
21. Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE, Hoffman KE. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol 2(3):249-258, 2017. e-Pub 2017. PMID: 29114589.
22. Koh EH, Chen Y, Bader DA, Hamilton MP, He B, York B, Kajimura S, McGuire SE, Hartig SM. Mitochondrial activity in human white adipocytes is regulated by the Ubiquitin Carrier Protein 9/microRNA-30a axis. J Biol Chem. e-Pub 2016. PMID: 27758866.
23. Hamilton MP, Rajapakshe KI, Bader DA, Cerne JZ, Smith EA, Coarfa C, Hartig SM, McGuire SE. The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia 18(6):356-70, 2016. PMID: 27292025.
24. Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, Lund AH, Vang S, Stribolt K, Madsen MR, Laurberg S, McGuire SE, Ørntoft TF, Andersen CL. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. e-Pub 2016. PMID: 27396952.
25. McGuire SE. DNA Damage and Repair Pathway Profiles as Biomarkers in High-Risk Prostate Cancer. JAMA Oncol 2(4):1-2, 2016. e-Pub 2016. PMID: 26747678.
26. Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun 7:11612, 2016. e-Pub 2016. PMID: 27194471.
27. Hartig SM, Hamilton MP, Bader DA, McGuire SE. The miRNA Interactome in Metabolic Homeostasis. Trends Endocrinol Metab 26(12):733-45, 2015. e-Pub 2015. PMID: 26492831.
28. Hartig SM, Bader DA, Abadie KV, Motamed M, Hamilton MP, Long W, York B, Mueller M, Wagner M, Trauner M, Chan L, Bajaj M, Moore DD, Mancini MA, McGuire SE. Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Mol Endocrinol 29(9):1320-33, 2015. e-Pub 2015. PMID: 26192107.
29. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell 26(6):863-79, 2014. PMID: 25490449.
30. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol 4(6):e239-46, 2014. e-Pub 2014. PMID: 25407875.
31. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; [Akbani R, Aldape KD, Baggerly KA, Broom BM, Chin L, Edgerton ME, Hamilton SR, Liang H, Liu Y, Lu Y, McGuire SE, Su X, Verhaak R, Wang W, Wu CJ, Yung WK, Zhang N, Zhang W] Cancer Genome Atlas Research Network*, Benz CC, Perou CM, Stuart JM. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Collaborator on behalf of the Cancer Genome Atlas Pan-Cancer Analysis Project. Cell 158(4):929-44, 2014. PMID: 25109877.
32. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified?. Eur Urol 65(6):1067-8, 2014. e-Pub 2013. PMID: 24411278.
33. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074-84, 2014. PMID: 24661661.
34. Cerne JZ, Hartig SM, Hamilton MP, Chew SA, Mitsiades N, Poulaki V, McGuire SE. Protein Kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation. Invest Ophthalmol Vis Sci 55(4):2130-9, 2014. e-Pub 2014. PMID: 24595385.
35. Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. e-Pub 2014. PMID: 24732810.
36. Coarfa C, Pichot C, Jackson A, Tandon A, Amin V, Raghuraman S, Paithankar S, Lee AV, McGuire SE, Milosavljevic A. Analysis of interactions between the epigenome and structural mutability of the genome using genboree workbench tools. BMC Bioinformatics 15(7):1471-2105, 2014. e-Pub 2014. PMID: 25080362.
37. Bader DA, Cerne JZ, McGuire SE. Recent Developments in Androgen Deprivation Therapy for Locally Advanced Prostate Cancer. Oncology & Hematology Review 10(2):133-8, 2014.
38. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 87(5):946-53, 2013. e-Pub 2013. PMID: 24139077.
39. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis 16(4):346-51, 2013. e-Pub 2013. PMID: 23939133.
40. Weinstein JN, Collison EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM, [Akbani R, Aldape KD, Baggerly KA, Broom BM, Chin L, Edgerton ME, Hamilton SR, Liang H, Liu Y, Lu Y, McGuire SE, Su X, Verhaak R, Wang W, Wu CJ, Yung WK, Zhang N, Zhang W. Cancer Genome Atlas Research Network*. The Cancer Genome Atlas Pan-Cancer analysis project. *Collaborator on behalf of the Cancer Genome Atlas Pan-Cancer Analysis Project. Nature Genetics 45(10):1113-20, 2013. PMID: 24071849.
41. Nguyen QN, Levy LB, Lee AK, Choi S, Frank SJ, Pugh TJ, McGuire SE, Hoffman KE, Kuban DA. Long-term Outcomes For Men With High-Risk Prostate Cancer Treated Definitively With External Beam Radiotherapy With and Without Androgen Deprivation. Cancer 119(18):3265-71, 2013. PMID: 23798338.
42. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 12(3):204-9, 2013. e-Pub 2012. PMID: 22673704.
43. Hartig SM, Feng Q, Ochsner SA, Xiao R, McKenna NJ, McGuire SE, He B. Androgen receptor agonism promotes an osteogenic gene program in preadipocytes. Biochem Biophys Res Commun 434(2):357-62, 2013. e-Pub 2013. PMID: 23567971.
44. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Radiat Oncol Biol Phys 85(3):693-9, 2013. e-Pub 2012. PMID: 22836052.
45. Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ. Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer. Med Dosim 38(3):251-4, 2013. e-Pub 2013. PMID: 23540491.
46. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 2013. e-Pub 2012. PMID: 23102837.
47. Hamilton MP, Rajapakshe K, Hartig SM, Reva B, McLellan MD, Kandoth C, Ding L, Zack TI, Gunaratne PH, Wheeler DA, Coarfa C, McGuire SE. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun 4(4):2730, 2013. PMID: 24220575.
48. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation theray to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 23(9):2346-52, 2012. e-Pub 2012. PMID: 22357249.
49. Hartig SM, He B, Newberg JY, Ochsner SA, Loose DS, Lanz RB, McKenna NJ, Buehrer BM, McGuire SE, Marcelli M, Mancini MA. Feed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes. Chem Biol 19(9):1126-41, 2012. PMID: 22999881.
50. Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat 135(1):135-43, 2012. e-Pub 2012. PMID: 22706629.
51. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. Eur J Cancer 48(11):1664-71, 2012. e-Pub 2012. PMID: 22336663.
52. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol 2(3):e7-e13, 2012. e-Pub 2012. PMID: 24674130.
53. Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. A SNP in steroid receptor co-activator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol 26(2):220-227, 2012. e-Pub 2011. PMID: 22174377.
54. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, 2012. PMID: 22290249.
55. Hartmaier RJ, Tchatchou S, Richter AS, Wang J, McGuire SE, Skaar TC, Rae JM, Hemminki K, Sutter C, Ditsch N, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, Wappenschmidt B, Schmutzler RK, Meindl A, Bartram CR, Burwinkel B, Oesterreich S. Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. BMC Cancer 9(9):438, 2009. e-Pub 2009. PMID: 20003447.
56. McGuire SE, McGuire AL. Don't throw the baby out with the bathwater: enabling a bottom-up approach in genome-wide association studies. Genome Res 18(11):1683-5, 2008. PMID: 18974262.
57. McGuire SE, Frank SJ, Eifel PJ. Treatment of recurrent vaginal melanoma with external beam radiation therapy and palladium-103 brachytherapy. Brachytherapy 7(4):359-63, 2008. e-Pub 2008. PMID: 18778972.
58. Zhang X, Zhao KL, Guerrero TM, McGuire SE, Yaremko B, Komaki R, Cox JD, Hui Z, Li Y, Newhauser WD, Mohan R, Liao Z. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72(1):278-87, 2008. PMID: 18722278.
59. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 95(4):433-7, 2008. PMID: 18161887.
60. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13(1):6-15, 2008. PMID: 18245008.
61. McGuire AL, Cho MK, McGuire SE, Caulfield T. The future of personal genomics. Science 317(5845)(1687):1687, 2007. PMID: 17885116.
62. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-9, 2007. e-Pub 2007. PMID: 17418973.
63. Alkhatib AA, McGuire SE. Photo Quiz. Sine waves. Neth J Med 65(4):153, 155, 2007. PMID: 17452766.
64. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28):7098-104, 2005. PMID: 16192593.
65. McGuire SE, Deshazer M, Davis RL. Thirty years of olfactory learning and memory research in drosophila melanogaster. Prog Neurobiol 76(8):328-47, 2005. e-Pub 2005. PMID: 16266778.
66. McGuire SE, Roman G, Davis RL. Gene expression systems in drosophila: a synthesis of time and space. Trends Genet 20(8):384-91, 2004. PMID: 15262411.
67. McGuire SE, Mao Z, Davis RL. Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in Drosophila. Sci STKE 2004(220):pl6, 2004. e-Pub 2004. PMID: 14970377.
68. McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal rescue of memory dysfunction in Drosophila. Science 302(302(5651)):1765-8, 2003. PMID: 14657498.
69. McGuire SE, Davis RL. Presenilin-1 and memories of the forebrain. Neuron 32(5):763-5, 2001. PMID: 11738022.
70. McGuire SE, Le PT, Davis RL. The role of Drosophila mushroom body signaling in olfactory memory. Science 293(5533):1330-3, 2001. e-Pub 2001. PMID: 11397912.
71. Lee AV, Weng CN, McGuire SE, Wolf DM, Yee D. Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor. Biotechniques 23(6):1062-8, 1997. PMID: 9421637.
72. Yee D,McGuire SE Brünner N, Kozelsky TW, Allred DC, Chen SH, Woo SL. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 7(10):1251-7, 1996. PMID: 8793549.
73. Lehming N,McGuire SE, Brickman JM, Ptashne M.. Interactions of a Rel protein with its inhibitor. Proc Natl Acad Sci U S A 92(22):10242-6, 1995. PMID: 7479760.
74. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett 77(1):25-32, 1994. PMID: 7512885.
75. McGuire SE, Fuqua SA, Naylor SL, Helin-Davis DA, McGuire WL. Chromosomal assignments of human 27-kDa heat shock protein gene family. Somat Cell Mol Genet 15(2):167-71, 1989. PMID: 2538929.

Invited Articles

1. McGuire SE, Buchholz TA.. Postsurgical radiation therapy in patients with complete response to neoadjuvant chemotherapy. Current Breast Cancer Reports 1(86-89):1946-4588, 2009.

Abstracts

1. Holliday EB, Kuban DA, Levy LB, Bolukbasi Y, Master P, Choi S, Nguyen Q, McGuire SE, Mahmood U, Frank SJ, Hoffman KE.. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis 4:384-394. e-Pub 2017. PMID: 28462945.
2. Voong KR1, Lal LS2, Kuban DA3, Pugh TJ3, Swint JM2,4, Godby J3, Choi S3, Lee AK3, Schlembach PJ3, Frank SJ3, McGuire SE3, Hoffman KE3.. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol 2(3):249-258, 2017. PMID: 29114589.
3. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen GN, Frank SJ, Pugh T, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Rad Oncol Biol Phys 81(2):S 40 - S 41, 2011.
4. TJ Pugh, SJ Frank, M Achim, DA Kuban, AK Lee, S Choi, Q Nguyen, K Hoffman, SE McGuire DA Swanson. Prediction of Extraprostatic Extension in Intermediate Risk Prostate Cancer: The Evolving Role of Endorectal MRI. Int J Rad Oncol Biol Phys 81(2):S 398, 2011.
5. Kim MM, Hoffman KE, Levy LB, Frank SJ, Choi S, Nguyen QN, Pugh TJ, McGuire SE, Lee AK, Kuban DA. Prostate Cancer-Specific Mortality After Definitive Radiation Therapy: Who Dies of Disease?. Proceedings of the 2011 Genitourinary Cancers Symposium, 2011.
6. Kim MM, Hoffman KE, Levy LB, Master P, Frank SJ, Choi S, Nguyen QN, McGuire SE Lee AK, Kuban DA. Improvement in Prostate Cancer Outcomes Over Time: A Twenty-Year Analysis. Int J Rad Oncol Phys 78(3):S 191 (#1115), 2010. PMID: 23798338.
7. Ludwig MS, Lee AK, McGuire SE, Choi S, Nguyen QN, Frank SJ, Kuban DA. Influence of Prognostic Factors on Duration of Hormone Therapy and Outcomes. Proceedings of the 92nd Annual Meeting of The American Radium Society, 2010.
8. Kuban DA, Noueras-Gonzalez GM, Hamblin L, Lee AK, Coi S, Frank SJ, Nguyen QN, Hoffman KE, McGuire SE, Munsell MF. Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer using Hypofractionation. Int J Rad Oncol Phys 78(3):S58 (#124), 2010.
9. McGuire SE, Levy LB, Settle SH, Choi S, Nguyen QN, Hoffman KE, Frank SJ, Lee AK, Kuban DA. PSA Response to Neoadjuvant Androgen Suppression Therapy Prior to High Dose Radiotherapy Predicts Survival in Clinically Localized High Risk Prostate Cancer. Int J Rad Oncol Phys 78(3):S 124 (#265), 2010.